1. Home
  2. IPO
  • Influx Healthtech Ltd IPO
Influx Healthtech Ltd IPO logo

Influx Healthtech IPO

  • Status: Closed
  • RHP:
  • ₹ 109,200 / 1200 shares

    Minimum Investment

IPO Listing Details

  • Listing Date

    25 Jun 2025

  • Listing Price

    ₹ 132.50

  • Listing Change

    38.02%

  • Last Traded Price

    ₹ 166.30

IPO Details

  • Open Date

    18 Jun 2025

  • Close Date

    20 Jun 2025

  • Listing Date

    25 Jun 2025

  • IPO Price Range

    ₹ 91 to ₹96

  • IPO Size

    ₹ 58.57 Cr

  • Listing Exchange

    NSE SME

Open Free Demat Account

+91
Resend OTP

By proceeding, you agree to all T&C*

hero_form
Timeline Subscription Status Financials SWOT FAQ Contacts

IPO Timeline

Influx Healthtech IPO Subscription Status

Last Updated: 20 June 2025 6:03 PM by 5paisa

Influx Healthtech Limited, which is led by Munir Abdul Ganee Chandniwala, is launching a ₹58.57 crore IPO via book building, comprising a fresh issue of 50 lakh shares and an offer for sale of 11 lakh shares. The company operates as a Contract Development and Manufacturing Organisation (CDMO) in the healthcare sector.
Its product portfolio spans nutraceuticals, cosmetics, veterinary feed, skincare, and herbal products. With three manufacturing units in Thane, Maharashtra, the company supports its clients from product development through regulatory support.
 

Established in: 2020
Managing Director: Munir Abdul Ganee Chandniwala

Peers
Sudarshan Pharma Industries Ltd
Quest Laboratories Limited
 

Objectives

Funding capex for the Nutraceutical manufacturing facility.
Funding capex for the Veterinary Food Division.
Purchase of machinery for the Homecare and Cosmetic Division.
General corporate purposes.


 

Influx Healthtech IPO Size

Types Size
Total IPO Size ₹58.57 Cr
Offer For Sale ₹10.56 Cr
Fresh Issue ₹48.00 Cr

 

Influx Healthtech IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 1200 ₹1,09,200
Retail (Max) 1 1200 ₹1,09,200
HNI (Min) 2 2400 ₹2,18,400

Influx Healthtech IPO Reservation

Investors Category Subscription (times) Shares Offered Shares bid for Total Amount (Cr.)*
QIB 137.87     11,59,200 15,98,18,400     1,534.26
NII (HNI) 481.10 8,70,000 41,85,55,200 4,018.13
Retail 117.68 20,29,200 23,87,97,600 2,292.46
Total** 201.35 40,58,400 81,71,71,200 7,844.84

 

*The "Shares Offered" and "Total Amount" are calculated using the upper limit of the issue price range.
**Shares allocated to anchor investors (or market makers) are excluded from the total number of shares offered.

Profit and Loss

Balance Sheet

Particulars (in Rs. Crores) FY23 FY24 FY25
Revenue 76.07 100.10 104.99
EBITDA 10.72 16.96 20.57
PAT 7.20 11.22 13.37
Particulars (in Rs. Crores)] FY23 FY24 FY25
Total Assets 28.30 41.10 70.30
Share Capital 0.03 0.03 18.15
Total Borrowings 0.80 0.32 0.22
Particulars (in Rs. Crores FY23 FY24 FY25
Net Cash Generated From / (used in) operating activities 6.82 8.94 7.10
Net Cash Generated From / (used in) investing activities -4.88 -8.36 -8.65
Net Cash Generated From / (used in) financing activities 0.14 -0.53 -0.11
Net Increase (Decrease) In Cash And Cash Equivalents 2.08 0.06 -1.70


Strengths

1. Diversified product portfolio across healthcare, wellness, and cosmetic segments.
2. Strategically located manufacturing units.
3. End-to-end service offering from development to regulatory support.
4. Rapidly growing revenue and profitability metrics.
 

Weaknesses

1. Recently incorporated (2020), relatively new in the market.
2. Dependency on contract manufacturing as the primary model.
3. Low market visibility compared to more established peers.
4. With only three manufacturing units, rapid demand may strain capacity.
 

Opportunities

1. Rising demand in the nutraceutical and wellness sectors
2. Expansion opportunities in the veterinary and homecare verticals
3. Strengthening R&D and product innovation pipeline
4. End-to-end solutions offer a competitive edge in acquiring diversified clients.
 

Threats

1. Intense competition from pharma and FMCG giants
2. Regulatory hurdles and compliance complexities
3. Pricing pressure in the contract manufacturing space
4. Dependence on a few large clients may impact revenues if any exit.
 

1. Consistent revenue and PAT growth across FY23–FY25.
2. Strong diversification across product categories and divisions.
3. Established infrastructure with scale capacity.
4. Strategic capex for expansion into high-demand verticals.
5. Professional promoter group with deep industry experience.
 

1. India's nutraceutical and wellness markets are growing at double-digit rates.
2. Rising health awareness and lifestyle shifts are fueling demand.
3. Influx is well-positioned with a diverse product portfolio.
4. The company benefits from strong contract manufacturing capabilities.
5. The government's push for AYUSH and vet care boosts future growth potential.
 

Will You Apply for Influx Healthtech IPO?

Yes No Maybe

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
Resend OTP

By proceeding, you agree to all T&C*

footer_form

FAQs

Influx Healthtech IPO opens from June 18, 2025, to June 20, 2025.
 

The size of the Influx Healthtech IPO is ₹58.57 Cr.
 

The price of Influx Healthtech IPO is fixed at ₹91 to ₹96 per share

To apply for Influx Healthtech IPO, follow the steps below:

  • Log in to your 5paisa account and go to the current IPO section
  • Enter the number of lots and the price at which you wish to apply for Influx Healthtech IPO
  • Enter your UPI ID and submit the bid, with this your bid will be placed with the exchange
  • You will receive the mandate notification to transfer the funds to your UPI account.
     

The minimum lot size of Influx Healthtech IPO is 1,200 shares with a minimum retail investment of ₹1,09,200.    

The allotment date of Influx Healthtech IPO is expected to be finalised June 23, 2025.
 

The tentative listing date of Influx Healthtech IPO is June 25, 2025, on the NSE SME platform.
 

Rarever Financial Advisors Pvt. Ltd. is the book-running lead manager of Influx Healthtech IPO. 
 

Influx Healthtech plans to utilise the IPO proceeds towards:

  • Setting up manufacturing for the Nutraceutical and Veterinary Divisions.
  • Equipment purchase for the Cosmetic/Homecare unit.
  • General corporate use.